SIGHT SCIENCES INC. - COMMON STOCK

Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry

06 مايو 2023 10:30:00 بحسب Nasdaq GlobeNewswire

Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

04 مايو 2023 15:05:01 بحسب Nasdaq GlobeNewswire

Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

01 مايو 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference

26 أبريل 2023 15:05:01 بحسب Nasdaq GlobeNewswire

Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023

20 أبريل 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023

13 أبريل 2023 15:05:41 بحسب Nasdaq GlobeNewswire

Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

03 أبريل 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office

30 مارس 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results

13 مارس 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System

09 مارس 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023

23 فبراير 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference

22 فبراير 2023 15:05:01 بحسب Nasdaq GlobeNewswire

Sight Sciences Announces 1,000th TearCare® Customer Installation

26 يناير 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results

09 يناير 2023 15:20:00 بحسب Nasdaq GlobeNewswire

Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCare® Treatment Sustained Through 12 Months

08 ديسمبر 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Piper Sandler 34th Annual Healthcare Conference

22 نوفمبر 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Sight Sciences Reports Third Quarter 2022 Financial Results

10 نوفمبر 2022 15:05:02 بحسب Nasdaq GlobeNewswire

Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure

03 نوفمبر 2022 07:30:01 بحسب Nasdaq GlobeNewswire

Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022

20 أكتوبر 2022 16:20:54 بحسب Nasdaq GlobeNewswire

Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED)

29 سبتمبر 2022 07:30:00 بحسب Nasdaq GlobeNewswire